qrx003
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
3
Phase 4
0
Earliest trial started Jun 23, 2022 (NCT05521438)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Kallikrein 1INHIBITOR
KLK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06953466 | Phase 2/Phase 3 (Phase 3) | Jul 31, 2025 | Quoin Pharmaceuticals |
| NCT05789056 | Phase 2/Phase 3 (Phase 3) | Mar 14, 2023 | Quoin Pharmaceuticals, Therapeutics, Inc. |
| NCT05521438 | Phase 2/Phase 3 (Phase 3) | Jun 23, 2022 | Quoin Pharmaceuticals, Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Quoin Pharmaceuticals | For profit | 3 | 3 | 1 | 2022 |
| Therapeutics, Inc. | For profit | 2 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1